Key facts
- Iambic’s last known valuation is $648.0M (Apr 2026).
- It has raised $354.8M across 2 recorded rounds; the latest was Early Stage VC ($38.4M) in Apr 2024.
- Notable investors include Alumni Ventures, Sequoia Capital, Coatue Management, Nvidia, Alexandria Venture Investments — 31 tracked in total.
- Iambic has filed 4 Form Ds with the SEC since 2023, most recently Jun 2024 ($38.4M sold to 11 investors).
- Status: Privately Held (backing).
Leadership
- Michael SecoraChief Financial Officer & Corporate Development Officer
- Neil JosephsonChief Medical Officer
- Peter OlsonChief Scientific Officer
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 31 names
- ·Watchlist + deal alerts for Iambic
Funding rounds
2 roundsAbout Iambic
Developer of an artificial intelligence-driven platform designed to address design problems in drug discovery, leveraging technology innovations. The company's engine combines artificial intelligence-driven technology and automated synthetic development to design small-molecule therapeutics, enabling physicians to get molecular predictions with speed and accuracy.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 142
- Website
- iambic.ai/
- Ownership
- Privately Held (backing)
Iambic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iambic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iambic in its N-PORT filings yet. We sweep new filings monthly.